Pensionmark Financial Group, LLC Relmada Therapeutics, Inc. Transaction History

Pensionmark Financial Group, LLC

$3.09 Billion
Q3 2024

A detailed history of Pensionmark Financial Group, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Pensionmark Financial Group, LLC holds 32,684 shares of RLMD stock, worth $90,207. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,684

Previous 32,684 -0.0%

Holding current value

$90,207

Previous $105,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $4.36 $4,600 - $8,720	2,000 Added 6.52%	32,684 $105,000
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $95,120 - $208,651	30,684 New	30,684 $142,000
Q2 2022 Aug 09, 2022	SELL	$16.5 - $30.34 $24,750 - $45,510	-1,500 Reduced 10.56%	12,700 $312,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $4,372 - $6,954	200 Added 1.43%	14,200 $372,000
Q2 2021 Aug 12, 2021	SELL	$29.55 - $39.15 $14,775 - $19,575	-500 Reduced 3.45%	14,000 $448,000
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $52,008 - $64,812	-1,650 Reduced 10.22%	14,500 $486,000
Q4 2020 Feb 16, 2021	SELL	$29.88 - $39.8 $10,458 - $13,929	-350 Reduced 2.12%	16,150 $589,000
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $13,768 - $17,512	-400 Reduced 2.37%	16,500 $621,000
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $91,611 - $144,942	2,900 Added 20.71%	16,900 $630,000
Q1 2020 Apr 23, 2020	BUY	$23.78 - $50.12 $23,780 - $50,120	1,000 Added 7.69%	14,000 $478,000
Q4 2019 Feb 13, 2020	BUY	$10.1 - $47.18 $131,300 - $613,340	13,000 New	13,000 $507,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $79M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pensionmark Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pensionmark Financial Group, LLC with notifications on news.

Account

Pensionmark Financial Group, LLC Relmada Therapeutics, Inc. Transaction History